https://youtu.be/gtE3SROFPXg

New resource available view now
Related Posts

POTOMAC, Maryland – August 28, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics and AI-enabled tools for Alzheimer’s disease, today announced

Alzheimer’s Across Borders: A Global look at regional patterns and drivers of Alzheimer’s Disease
Regional differences in Alzheimer’s Disease prevalence are often linked with factors such as health infrastructure, socioeconomic status, and lifestyle choices. Addressing these disparities requires a deeper understanding of how culture,

Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding

POTOMAC, Maryland – August 11, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing treatments for Alzheimer’s disease, today announced that it is

POTOMAC, Maryland – July 29, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced that it is